Odonate Therapeutics, Inc. ODT
1.12 0.00 (+0.00%)
Apr 24, 2025, 3:47 PM EDT
1.11 Day range 1.20
52-week range unavailable
- Market cap
- 43.11M
- Shares out
- 38.49M
- Forward P/E
- -14.00
- Volume
- 716.44K
- Open
- 1.16
- Previous close
- 1.12
- Day's range
- 1.11 – 1.20
- Beta
- 0.45
- Analysts
- Hold
- Price target
- 4.00 (+257.1%)
- Earnings date
- Jan 4, 2023
2Y -2.18 (-66.06%)
Key statistics
- Enterprise value
- -47.07M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -44.03M
- Total cash
- 95.03M
- Total debt
- 4.85M
- Return on equity
- -86.14%
- Short % of float
- 2.30%
- 50-day average
- 1.39
- 200-day average
- 2.81
Analyst view
Consensus: hold
Hold
Price target (mean) 4.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Jan 4, 2023
Expected Jan 4, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 4, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Jul 27, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2019 | Empire Asset Management | init | — | Sell |
| Jan 2, 2018 | Goldman Sachs | init | — | Neutral |
| Jan 2, 2018 | Cowen & Co. | init | — | Outperform |
| Jan 2, 2018 | Jefferies | init | — | Buy |
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- odonate.com
News
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript 
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder 
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results 
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst 
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder 
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder 
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema 
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder 
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
Your note
Sign in to keep a note on ODT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOXER CAPITAL L L C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 29, 2020 | 0 |
| DAVIS AARON I | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 29, 2020 | 0 |
| HEARNE MICHAEL S. | Chief Financial Officer | Stock Award(Grant) | Mar 14, 2021 | 15,517,200 |
| JOHNSON CRAIG A | Director | Purchase | Dec 28, 2020 | 3,000 |
| LEMKEY JOHN G | Chief Operating Officer | Stock Award(Grant) | Nov 29, 2020 | 15,242,200 |
| O'CONNELL JOSEPH P | Officer | Stock Award(Grant) | Mar 14, 2021 | 3,610 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 40.31% | 15,514,566 | 45.15M | Sep 29, 2021 |
| Boxer Capital, LLC | 14.57% | 5,607,086 | 16.32M | Sep 29, 2021 |
| EcoR1 Capital, LLC | 9.68% | 3,727,261 | 10.85M | Sep 29, 2021 |
| Ikarian Capital, LLC | 4.78% | 1,840,631 | 5.36M | Sep 29, 2021 |
| Vanguard Group, Inc. (The) | 2.50% | 962,199 | 2.80M | Sep 29, 2021 |
| Blackrock Inc. | 1.90% | 731,497 | 2.13M | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.17% | 449,600 | 1.31M | Sep 29, 2021 |
| Vanguard Extended Market Index Fund | 0.83% | 319,901 | 930.91K | Sep 29, 2021 |
| iShares NASDAQ Biotechnology ETF | 0.79% | 305,625 | 938.27K | Oct 30, 2021 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.42% | 161,720 | 470.61K | Sep 29, 2021 |
| Fidelity Extended Market Index Fund | 0.42% | 160,571 | 492.95K | Oct 30, 2021 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.21% | 81,261 | 281.98K | Aug 30, 2021 |